324 related articles for article (PubMed ID: 25224570)
1. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
[TBL] [Abstract][Full Text] [Related]
2. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR
PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460
[TBL] [Abstract][Full Text] [Related]
3. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
4. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
[TBL] [Abstract][Full Text] [Related]
5. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.
Naghibi L; Yazdani M; Momtazi-Borojeni AA; Razazan A; Shariat S; Mansourian M; Arab A; Barati N; Arabsalmani M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
PLoS One; 2020; 15(12):e0243550. PubMed ID: 33301467
[TBL] [Abstract][Full Text] [Related]
6. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.
Farzad N; Barati N; Momtazi-Borojeni AA; Yazdani M; Arab A; Razazan A; Shariat S; Mansourian M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):665-673. PubMed ID: 30829072
[TBL] [Abstract][Full Text] [Related]
7. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
[TBL] [Abstract][Full Text] [Related]
8. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids.
Yazdani M; Jalali SA; Badiee A; Shariat S; Mansourian M; Arabi L; Abbasi A; Saberi Z; Jaafari MR
Curr Drug Deliv; 2017; 14(4):492-502. PubMed ID: 27411392
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects.
Shariat S; Badiee A; Amir Jalali S; Mansourian M; Alireza Mortazavi S; Reza Jaafari M
Iran J Basic Med Sci; 2015 May; 18(5):506-13. PubMed ID: 26124938
[TBL] [Abstract][Full Text] [Related]
11. Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer.
Rastakhiz S; Yazdani M; Shariat S; Arab A; Momtazi-Borojeni AA; Barati N; Mansourian M; Amin M; Abbasi A; Saberi Z; Jalali SA; Badiee A; Jaafari MR
J Cell Biochem; 2019 Feb; 120(2):1294-1303. PubMed ID: 30378147
[TBL] [Abstract][Full Text] [Related]
12. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
13. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
Mossman SP; Evans LS; Fang H; Staas J; Tice T; Raychaudhuri S; Grabstein KH; Cheever MA; Johnson ME
Vaccine; 2005 May; 23(27):3545-54. PubMed ID: 15855013
[TBL] [Abstract][Full Text] [Related]
14. [Cytotoxic activity of spleen lymphocytes in BALB/c mice immunized by HSP110-HER2/neu ICD].
Han D; Xu H; Yan WQ
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):11-4. PubMed ID: 22490848
[TBL] [Abstract][Full Text] [Related]
15. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Silla S; Fallarino F; Boon T; Uyttenhove C
Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
[TBL] [Abstract][Full Text] [Related]
16. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
[TBL] [Abstract][Full Text] [Related]
19. Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits.
Caglar K; Aybay C; Ataoglu H
APMIS; 2005 Apr; 113(4):256-63. PubMed ID: 15865606
[TBL] [Abstract][Full Text] [Related]
20. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes.
Zhou F; Huang L
Vaccine; 1993; 11(11):1139-44. PubMed ID: 8249434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
